Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of CS-1008 in Japanese Patients With Solid Cancer
jRCT2080220861Phase 1
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tigatuzumab in Non-hematologic malignancy and metastasis, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Safety and tolerability of tigatuzumab (CS-1008) and Pharmacokinetics of tigatuzumab (CS-1008).
02
Drugs
tigatuzumab
03
Conditions
Non-hematologic malignancymetastasis
Beyond the preview
Go deeper on jRCT2080220861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220861.